Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 10, 2006

Siga Receives $2.3M from the U.S. Air Force

  • Siga Technologies received two contracts from the U.S. Air Force for a total of $2.3 million. A $1.4-million agreement covers the development of counter-measures against potential biowarfare pathogens, the Dengue viruses, and other water-related viral agents. Siga also won a one-year, $900,000 contract to aid the USAF Special Operations Command in its development of specific antiviral agents, focusing on orthopoxvirus targets distinct from the target that is the focus of SIGA-246, the company’s lead smallpox drug.

    Dengue fever and Dengue hemorrhagic fever are acute febrile mosquito-borne diseases caused by one of four closely related virus serotypes of the genus Flaviviridae. The two diseases affect tens of millions of people worldwide every year and present a biodefense threat in the U.S. Currently, there is no approved drug or vaccine against Dengue, leaving troops vulnerable overseas and in areas affected by flooding, according to Siga.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »